Discoidin domain receptor 2 and its expression and role in tumor

Abstract

WANG Lei, LIU Dong-Ming. Discoidin domain receptor 2 and its expression and role in tumor[J]. Journal of International Oncology, 2016, 43(2): 126-.

［1］ Valiathan RR, Marco M, Leitinger B, et al. Discoidin domain receptor tyrosine kinases: new players in cancer progression［J］. Cancer Metastasis Rev， 2012, 31(12):295321. DOI:10.1007/s105550129346z. ［2］ Ikeda K, Wang LH, Torres R, et al. Discoidin domain receptor 2 interacts with Src and Shc following its activation by type Ⅰ collagen［J］. J Biol Chem， 2002, 277(21):1920619212. DOI:10.1074/jbc.M201078200. ［3］ Mishra VK, Johnsen SA.Targeted therapy of epigenomic regulatory mechanisms controlling the epithelial to mesenchymal transition during tumor progression［J］.Cell Tissue Res, 2014, 356(3):617630. DOI:10.1007/s004410141912y. ［4］ Liu XQ, Fan DM. The epithelialmesenchymal transition and cancer stem cells: functional and mechanistic links［J］.Curr Pharm Des, 2015, 21(10):12791291. ［5］朱蕾, 隋华, 邓皖利. 信号通路调控上皮间质转化参与肿瘤侵袭转移的分子机制［J］. 国际肿瘤学杂志， 2014, 41(3):172177. DOI: DOI:10.3760/cma.j.issn.1673422X.2014.03.004. ［6］ Walsh LA, Nawshad A, Medici D. Discoidin domain receptor 2 is a critical regulator of epithelialmesenchymal transition［J］. Matrix Biol， 2011, 30(4):243247. DOI:10.1016/j.matbio.2011.03.007. ［7］任婷婷. DDR2在肿瘤低氧适应中的作用研究［D］.西安: 第四军医大学， 2010. ［8］ Maeyama M, Koga H, Selvendiran K, et al. Switching in discoid domain receptor expressions in SLUGinduced epithelialmesenchymal transition［J］. Cancer， 2008, 113(10):28232831. DOI:10.1002/cncr.23900. ［9］ Davies H, Hunter C, Smith R, et al. Somatic mutations of the protein kinase gene family in human lung cancer［J］. Cancer Res， 2005, 65(17):75917595. DOI:10.1158/00085472.CAN051855. ［10］ Ford CE, Lau SK, Zhu CQ, et al. Expression and mutation analysis of the discoidin domain receptors 1 and 2 in nonsmall cell lung carcinoma［J］. Br J Cancer, 2007, 96(5):808814. DOI:10.1038/sj.bjc.6603614. ［11］ Sasaki H, Shitara M, Yokota K, et al. DDR2 polymorphisms and mRNA expression in lung cancers of Japanese patients［J］. Oncol Lett， 2012, 4(1):3337. DOI:10.3892/ol.2012.684. ［12］ Hammerman PS, Sos ML, Ramos AH, et al. Mutations in the DDR2 kinase gene identify a Novel therapeutic target in squamous cell lung cancer［J］. Cancer discov， 2011, 1(1):7889. DOI:10.1158/21598274.CD110005. ［13］ Pitini V, Arrigo C, Di Mirto C, et al. Response to dasatinib in a patient with SQCC of the lung harboring a discoidreceptor2 and synchronous chronic myelogenous leukemia［J］. Lung Cancer， 2013, 82(1):171172. DOI:10.1016/j.lungcan.2013.07.004. ［14］ An SJ, Chen ZH, Su J, et al. Identification of enriched driver gene alterations in subgroups of nonsmall cell lung cancer patients based on histology and smoking status［J］. PLoS One， 2012, 7(6):e40109. DOI:10.1371/journal.pone.0040109. ［15］ Chua HH, Yeh TH, Wang YP, et al. Upregulation of discoidin domain receptor 2 in nasopharyngeal carcinoma［J］. Head Neck, 2008, 30(4):427436. DOI:10.1002/hed.20724. ［16］ Xu J, Lu W, Zhang S, et al. Overexpression of DDR2 contributes to cell invasion and migration in head and neck squamous cell carcinoma［J］. Cancer Biol Ther， 2014, 15(5):612622. DOI:10.4161/cbt.28181. ［17］ Park HS, Kim KR, Lee HJ, et al. Overexpression of discoidin domain receptor 1 increases the migration and invasion of hepatocellular carcinoma cells in association with matrix metalloproteinase［J］. Oncol Rep， 2007, 18(6):14351441. ［18］ Lee NO, Park JW, Lee JA, et al. Dual action of a selective cyclooxygenase2 inhibitor on vascular endothelial growth factor expression in human hepatocellular carcinoma cells: novel involvement of discoidin domain receptor 2［J］. J Cancer Res Clin Oncol, 2012, 138(1):7384. DOI:10.1007/s0043201110750. ［19］ Park JW, Lee YS, Kim JS, et al. Downregulation of discoidin domain receptor 2 decreases tumor growth of hepatocellular carcinoma［J］. J Cancer Res Clin Oncol, 2015, 141(11):19731983. DOI:10.1007/s0043201519675. ［20］武曼群, 杨少奇, 赵进, 等. 盘状结构域受体在人肝癌、肝硬化与正常肝组织中的表达及其意义［J］.宁夏医学杂志, 2014, 36(9):824826. ［21］ Ren T, Zhang J, Zhang J, et al. Increased expression of discoidin domain receptor 2 (DDR2): a novel independent prognostic marker of worse outcome in breast cancer patients［J］. Med Oncol, 2013, 30(1):397. DOI:10.1007/s1203201203973. ［22］ Ren T, Zhang W, Liu X, et al. Discoidin domain receptor 2 (DDR2) promotes breast cancer cell metastasis and the mechanism implicates epithelialmesenchymal transition programme under hypoxia［J］. J Pathol, 2014, 234(4):526537. DOI:10.1002/path.4415. ［23］ Zhang K, Corsa CA, Ponik SM, et al. The collagen receptor discoidin domain receptor 2 stabilizes SNAIL1 to facilitate breast cancer metastasis［J］. Nat Cell Biol, 2013, 15(6):677687. DOI:10.1038/ncb2743. ［24］ Toy KA, Valiathan RR, Núez F, et al. Tyrosine kinase discoidin domain receptors DDR1 and DDR2 are coordinately deregulated in triplenegative breast cancer［J］. Breast Cancer Res Treat， 2015, 150(1):918. DOI:10.1007/s1054901532857. ［25］ Yan Z, Jin S, Wei Z, et al. Discoidin domain receptor 2 facilitates prostate cancer bone metastasis via regulating parathyroid hormonerelated protein［J］. Biochim Biophys Acta， 2014, 1842(9):13501363. DOI:10.1016/j.bbadis.2014.04.018.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying. Research progress of habitat analysis in radiomics of malignant tumors [J]. Journal of International Oncology, 2024, 51(5): 292-297.

Discoidin domain receptor 2 and its expression and role in tumor

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments